Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Wong Roderick
Relationship:   10% Owner
City:   Patterson
State:   NY
   
Insider Summary:
  
   
Companies Owned :   15    
Direct Shares   0    

Indirect Shares

   57,532,221      
Direct Value   $0    

Indirect Value

   $1,241,375,912      
Total Shares   57,532,221      
Total Value   $1,241,375,912      


                                          Charting Not Avaliable
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    6   
    0    

     Stock price went up :
    3   
    0    
     Stock price went down :
    3   
    0    
   
     Gain/Loss Ratio :
   0.0   
   0.0   
     Percentage Gain/Loss :
   13.0%
   0.0%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Penwest Pharmaceuticals Co PPCO Director 2010-09-20 0 2010-06-30 0    Premium*  
            Milestone Pharmaceuticals Inc. MIST 10% Owner 2019-05-09 0 2023-03-22 3,256,102    Premium*  
            Stoke Therapeutics, Inc. STOK 10% Owner 2019-06-19 0 2019-11-08 3,544,248    Premium*  
            Dermtech Ord Shs DMTK 10% Owner 0 2022-11-04 3,018,666    Premium*  
            Immunovant Inc IMVT Chief Executive Office... 2019-11-07 0 2019-12-11 902,498    Premium*  
            Tela Bio, Inc. TELA 10% Owner 2019-12-13 0 2019-12-17 1,139,358    Premium*  
            Avidity Biosciences, Inc. RNA MP and CIO 2020-06-16 0 2021-08-04 4,795,000    Premium*  
            Athira Pharma, Inc. ATHA 10% Owner 0 2020-09-18 2,668,913    Premium*  
            Tarsus Pharmaceuticals, Inc. TARS 10% Owner 0 2021-05-07 2,013,601    Premium*  
            Landos Biopharma, Inc. LABP 10% Owner 2021-02-04 0 2022-09-23 3,975,722    Premium*  
            Prometheus Biosciences, Inc. RXDX 10% Owner 2021-03-16 0 2021-03-16 3,264,031    Premium*  
            Renovacor Ord Shs RCOR 10% Owner 2021-09-02 0 2022-12-01 0    Premium*  
            Orchestra BioMed Holdings Inc. OBIO 10% Owner 2022-07-22 0 2023-04-13 5,620,645    Premium*  
            Rocket Pharmaceuticals RCKT Director, 10% Owner 2022-10-06 0 2023-08-28 18,157,605    Premium*  
            Cargo Therapeutics, Inc. CRGX 10% Owner 0 2024-01-12 5,175,832    Premium*  
* Premium Members only  

Records found :    93         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 1 of 4
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
PPCO Penwest Pharmaceuticals C... Director   –       •      –    2010-09-20 4 D $0.00 $0 D/D (20,000) 0 0 -
RCOR Renovacor Ord Shs 10% Owner   –       –       •   2022-12-01 4 D $0.00 $0 I/I (3,000,803) 0 0 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-07 4 B $10.18 $178,150 I/I 17,500 17,500 2.66 -
PPCO Penwest Pharmaceuticals C... Director   –       •      –    2010-06-30 4 A $0.00 $0 D/D 20,000 20,000 0 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-11 4 B $10.18 $132,340 I/I 13,000 30,500 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-12 4 B $10.17 $1,017,000 I/I 100,000 130,500 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-13 4 B $10.17 $132,210 I/I 13,000 143,500 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-14 4 B $10.17 $132,210 I/I 13,000 156,500 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-15 4 B $10.29 $133,800 I/I 13,000 169,500 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-18 4 B $10.25 $305,501 I/I 29,805 199,305 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-19 4 B $10.25 $305,501 I/I 29,805 229,110 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-20 4 B $10.39 $309,582 I/I 29,805 258,915 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-21 4 B $10.42 $158,299 I/I 15,194 274,109 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-22 4 B $10.54 $21,080 I/I 2,000 276,109 2.58 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-11-29 4 B $10.45 $281,293 I/I 26,918 315,027 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-12-02 4 B $10.40 $208,000 I/I 20,000 335,027 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-12-03 4 B $10.21 $204,200 I/I 20,000 355,027 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-12-04 4 B $10.15 $203,000 I/I 20,000 375,027 2.66 -
ATHA Athira Pharma, Inc. 10% Owner   –       –       •   2020-09-17 3 IO $0.00 $0 I/I 0 383,782 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-12-05 4 B $10.15 $203,000 I/I 20,000 395,027 2.66 -
LABP Landos Biopharma, Inc. Director   –       •       •   2021-02-04 4 B $16.00 $10,000,000 I/I 625,000 625,000 2.25 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-12-06 4 B $10.25 $4,100,000 I/I 400,000 795,027 2.66 -
RXDX Prometheus Biosciences, I... 10% Owner   –       –       •   2021-03-16 4 B $19.00 $15,200,000 I/I 800,000 800,000 1.5 %
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-12-06 4 B $10.20 $510,125 I/I 50,000 845,027 2.66 -
IMVT Immunovant Inc Chief Executive Officer   •       •      –    2019-12-10 4 B $10.38 $269,517 I/I 25,971 870,998 2.66 -
  93  Records found
  1  2   3   4      
  Page 1 of 4  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us